[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.120.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 1997

A New Immunocompetent Murine Model for Oral Cancer

Author Affiliations

From the Departments of Otolaryngology—Head and Neck Surgery, The Johns Hopkins University, Baltimore, Md (Dr O'Malley) and the University of Pittsburgh, Pittsburgh, Pa (Ms Cope and Dr Johnson), and the Department of Pathology, Baylor College of Medicine, Houston, Tex (Dr Schwartz).

Arch Otolaryngol Head Neck Surg. 1997;123(1):20-24. doi:10.1001/archotol.1997.01900010022003
Abstract

Objective:  To develop and characterize a new immunocompetent murine model that attempts to parallel the clinical and biological nature of head and neck cancer.

Design:  The growth rate and histologic characteristics of the SCC VII/SF cell line were initially determined in tissue culture experiments. Animal experiments were subsequently performed on C3H/HeJ mice. Using direct injection, 5 ×105 SCC VII/SF cells were delivered to the floor of the mouth of each animal. Animals were killed after 1, 2, and 3 weeks, and tumor growth, invasion, and regional and distant metastases were evaluated.

Results:  Squamous cell carcinomas that could be palpated and measured externally were identified in the floor of the mouth of C3H/HeJ mice after 5 to 7 days. Local invasion into the mylohyoid musculature and mandible was present. Cervical lymph node and pulmonary metastases were identified between 2 and 3 weeks.

Conclusions:  This study introduces a new oral cancer animal model that shows initial locoregional tumor invasion, direct extension into the neck, early cervical metastases, and pulmonary metastases. These clinical and histopathologic attributes reflect the biological behavior and tumor progression seen in human oral cancer and therefore provide a model for clinically applicable research for primary and metastatic head and neck cancer.Arch Otolaryngol Head Neck Surg. 1997;123:20-24

×